REFERENCES
- Beck-Sague CM, Jarvis WR, the National Nosocomial Infections Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 1993; 167: 1247–51.
- Tariq VN, Scott EM, McCain NE. Use of decimal assay for additivity to demonstrate synergy in pair combinations of econazole, nikkomycin Z, and ibuprofen against Candida albicans in vitro. Antimicrob Agents Chemother 1995; 39: 2615–19.
- Swenson CE, Perkins WR, Roberts P, et al. In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important? Antimicrob Agents Chemother 1998; 42: 767–71.
- Hanson LH, Stevens DA. Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholestryl sulfate colloidal dispersion. Antimicrob Agents Chemother 1992; 36: 486–88.
- Georgopapadakou NH, Tkacz JS. The fungal cell wall as a drug target. Trends Microbiol 1995; 3: 98–104.
- Boken D, Swindells S, Rinaldi M. Fluconazole resistant Candida albicans. Clin Infect Dis 1993; 17: 1018–21.
- White TC. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother 1997; 41: 1482–87.
- Kelly SL, Lamb DC, Kelly DE, Loeffler J, Einsele H. Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients. Lancet 1996; 348: 1523–24.
- Vazquez JA, Arganoza MT, Vaishampayan JK, Akins RA. In vitro interaction between amphotericin B and azoles in Candida albicans. Antimicrob Agents Chemother 1996; 40: 2511–16.
- Polak A. Combination therapy for systemic mycosis. Infection 1989; 17: 203–9.
- Sanyal AK, Roy D, Chowdhury B, Banerjee AB. Ibuprofen, a unique antiinflammatory compound with antifungal activity against dermatophytes. Letts Appl Microbiol 1993; 17: 109–11.
- National Committee for Clinical Laboratory Standards. Reference method for broth dilution susceptibility testing of yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Villanova, PA, 1997.
- Moody JA. Synergism testing: broth microdilution checkerboard and broth macrodilution methods. In: Isenberg HD eds. Clinical Microbiology Procedures Handbook, 1” edn, Washington DC: ASM, 1992: volume 1, section 5.18 pp.5.18.1-28.
- Scott EM, Tariq VN, McCrory RM. Demonstration of synergy with fluconazole and either ibuprofen, sodium salicylate, or propylparaben against Candida albicans in vitro. Antimicrob Agents Chemother 1995; 39: 2610–14.
- Rieg G, Johnston D, Ibrahim A, Filler S, Edwards JEJr. In vitro activity of voriconazole in combination with amphotericin B or 5-flucytosine against clinical fluconazole-resistant Candida albicans. In Program and Abstracts of the 38th Annual ICAAC, San Diego, CA. Washington, DC. American Society for Microbiology, 1998; Abstract J-11, 453.
- Dean AG, Dean JA, Coulombier D, et al. Epi Info, version 6: a word processing, data base, and statistics program epidemiology on microcomputers. Centers for Disease Control and Prevention, Atlanta, Georgia, U.S.A., 1994.
- Hector RF, Schaller K. Positive interaction of nikkomycins and azoles against Candida albicans in vitro and in vivo. Antimicrob Agents Chemother 1992; 36: 1284–89.
- Brajtburg J, Kobayashi D, Medoff G, Kobayashi GS. Antifungal action of amphotericin B in combination with other polyene or imidazole antibiotics. J Infect Dis 1982; 146: 138–46.
- Ghannoum MA, Fu Y, Ibrahim AS, et al. In vitro determination of optimal antifungal combinations against Ctyptococcus neoformans and Candida albicans. Antimicrob Agents Chemother 1995; 39: 2459–65.
- Odds FC. Interactions among amphotericin B, 5-fluoro-cytosine, ketoconazole, and miconazole against pathogenic fungi in vitro. Antimicrob Agents Chemother 1982; 22: 763–70.
- Scheven M, Schwegler F. Antagonistic interactions between azoles and amphotericin B with yeast depend on azole lipophilic for special test conditions in vitro. Antimicrob Agents Chemother 1995; 39: 1779–83.